Q3332908 (Q3332908): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Created claim: summary (P836): A lack of precise diagnostic test for cancer early detection and therapy decision is the reason for high cancer-associated mortality rates. EMECK project is developing a novel mobile biochip analysis platform that combines established cancer markers from the clinic with markers of current clinical trials and AI-based diagnostics. Although marker panels are developed for pancreatic, intestinal and lunden carcinoma, it is possible to expand to oth...) |
||||||||||||||
| Property / summary | |||||||||||||||
A lack of precise diagnostic test for cancer early detection and therapy decision is the reason for high cancer-associated mortality rates. EMECK project is developing a novel mobile biochip analysis platform that combines established cancer markers from the clinic with markers of current clinical trials and AI-based diagnostics. Although marker panels are developed for pancreatic, intestinal and lunden carcinoma, it is possible to expand to other entities on the platform. (English) | |||||||||||||||
| Property / summary: A lack of precise diagnostic test for cancer early detection and therapy decision is the reason for high cancer-associated mortality rates. EMECK project is developing a novel mobile biochip analysis platform that combines established cancer markers from the clinic with markers of current clinical trials and AI-based diagnostics. Although marker panels are developed for pancreatic, intestinal and lunden carcinoma, it is possible to expand to other entities on the platform. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: A lack of precise diagnostic test for cancer early detection and therapy decision is the reason for high cancer-associated mortality rates. EMECK project is developing a novel mobile biochip analysis platform that combines established cancer markers from the clinic with markers of current clinical trials and AI-based diagnostics. Although marker panels are developed for pancreatic, intestinal and lunden carcinoma, it is possible to expand to other entities on the platform. (English) / qualifier | |||||||||||||||
point in time: 25 October 2021
| |||||||||||||||
Revision as of 07:55, 25 October 2021
Project Q3332908 in Germany
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3332908 in Germany |
Statements
375,262.22 Euro
0 references
798,430.26 Euro
0 references
47.0 percent
0 references
1 February 2021
0 references
30 June 2023
0 references
Campton Diagnostics GmbH
0 references
25524 Itzehoe
0 references
Ein Mangel an präzisen diagnotischen Test zur Krebsfrüherkennung und -therapieentscheidung ist der Grund für hohe krebsassoziierte Sterblichkeitsrate. Molukulare Marker in Flüssigbiopsien EMECK-Projekt wird eine neuartige mobile Biochip-Analyseplattform entwickelt, die etablierteKrebsmarker aus der Klinik mit Markern aktueller klinischer Studien kombiniert und KI-basiert eine Diagnostik stellen kann. Obwohl Markerpanels für das Pankreas-, Darm- und Lundenkarzinom entwickelt werden, ist eine Erweiterung auf andere Entitäten auf der Plattform möglich. (German)
0 references
A lack of precise diagnostic test for cancer early detection and therapy decision is the reason for high cancer-associated mortality rates. EMECK project is developing a novel mobile biochip analysis platform that combines established cancer markers from the clinic with markers of current clinical trials and AI-based diagnostics. Although marker panels are developed for pancreatic, intestinal and lunden carcinoma, it is possible to expand to other entities on the platform. (English)
25 October 2021
0 references
Identifiers
DE_TEMPORARY_35553
0 references